🇺🇸 FDA
Pipeline program

NOV-002

NOV002- IS21 -OC

Phase 2 small_molecule completed

Quick answer

NOV-002 for Ovarian Cancer is a Phase 2 program (small_molecule) at Cellectar Biosciences with 1 ClinicalTrials.gov record(s).

Program details

Company
Cellectar Biosciences
Indication
Ovarian Cancer
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials